Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 2;11(1):68-72.
doi: 10.1055/s-0041-1739365. eCollection 2022 Jan.

Therapeutic Outcomes in High-Grade B-Cell Lymphoma, NOS: Retrospective Analysis

Parathan Karunakaran  1 , Gangothri Selvarajan  1 , Jayachandran Perumal Kalaiyarasi  1 , Nikita Mehra  1 , Shirley Sundersingh  2 , Manikandan Dhanushkodi  1 , Sivasree Kesana  1 , Krishnarathinam Kannan  1 , Trivadi S Ganesan  1 , Venkatraman Radhakrishnan  1 , Tenali Gnana Sagar  1
Affiliations

Therapeutic Outcomes in High-Grade B-Cell Lymphoma, NOS: Retrospective Analysis

Parathan Karunakaran et al. South Asian J Cancer. .

Abstract

The nomenclature high-grade non-Hodgkin's lymphoma was repurposed in the World Health Organization (WHO) 2016 update as high-grade B cell lymphoma (HGBL). However, among the HGBL entities HGBL, not otherwise specified (NOS) remains a poorly described entity with a lack of literature regarding its treatment and prognosis. The baseline characteristics, treatment, and outcome of HGBL, NOS cases were analyzed. Thirty HGBL, NOS patients were diagnosed between January 2017 and December 2019. Their median age was 49.3 years, and 30% had advanced IPI. The majority received R-CHOP chemotherapy, while five patients received dose-adjusted R-EPOCH. At a median follow-up of 15 months, nine patients had disease progression or relapse. EFS and OS were 22 months (12.1-31.9 months) and 37 months (29.4-44.0 months) respectively. Only NCCN-IPI ≤ 2 showed significant influence on the outcome. The results were similar to the outcomes previously reported. This study highlights the importance of NCCN-IPI in ascertaining the prognosis of HGBL, NOS. The literature review suggests that more intensive chemotherapy is ideal for HGBL, NOS. However, prospective trials are needed to prove whether the treatment of HGBL, NOS can be tailored based on NCCN-IPI.

Keywords: DLBCL; HGBL; HGBL NOS; aggressive B cell lymphoma; high-grade B cell Lymphoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Overall survival and event-free survival curves of all 30 patients.
Fig. 2
Fig. 2
( A and B ) show overall survival and event-free survival curves for those with IPI score ≤ 1 and > 1, respectively. ( C and D ) show OS and EFS survival curves for those with NCCN-IPI score ≤ 2 and > 2, respectively.
See this image and copyright information in PMC

References

    1. Chen B J, Fend F, Campo E, Quintanilla-Martinez L. Aggressive B-cell lymphomas–from morphology to molecular pathogenesis. Ann Lymphoma. 2019;3:1–22.
    1. Swerdlow S H, Campo E, Pileri S A. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. - PMC - PubMed
    1. Swerdlow S H, Campo E, Harris N L.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th ed.Vol. 2.Lyon: IARC; 2017
    1. Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(04):235–242. - PubMed
    1. Wilson W H, Dunleavy K, Pittaluga S. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717–2724. - PMC - PubMed